Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)

被引：33

作者：

McCartney, Amelia ^{[1
]}

Biagioni, Chiara ^{[1
,2
]}

Schiavon, Gaia ^{[4
]}

Bergqvist, Mattias ^{[5
]}

Mattsson, Karin ^{[5
]}

Migliaccio, Ilenia ^{[3
]}

Benelli, Matteo ^{[2
]}

Romagnoli, Dario ^{[2
]}

Bonechi, Martina ^{[3
]}

Boccalini, Giulia ^{[3
]}

Pestrin, Marta ^{[1
,3
]}

Galardi, Francesca ^{[3
]}

De Luca, Francesca ^{[3
]}

Biganzoli, Laura ^{[1
]}

Piccart, Martine ^{[6
]}

Gradishar, William J. ^{[7
]}

Chia, Stephen ^{[8
]}

Di Leo, Angelo ^{[1
]}

Malorni, Luca ^{[1
,3
]}

机构：

[1] Hosp Prato, Sandro Pitigliani Med Oncol Dept, Via Suor Niccolina 20, I-59100 Prato, Italy

[2] Hosp Prato, Bioinformat Unit, Prato, Italy

[3] Hosp Prato, Translat Res Unit, Prato, Italy

[4] AstraZeneca, IMED Biotech Unit, Cambridge, England

[5] Biovica Int, Uppsala, Sweden

[6] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med Oncol, Brussels, Belgium

[7] Northwestern Univ, Dept Med, Chicago, IL 60611 USA

[8] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada

来源：

EUROPEAN JOURNAL OF CANCER | 2019年 / 114卷

关键词：

Breast cancer; Biomarker; Prognosis; Treatment response; Endocrine resistance; EFECT; THYMIDYLATE SYNTHASE; KI67;

D O I：

10.1016/j.ejca.2019.04.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Thymidine kinase 1 (TK1) plays a critical role in DNA synthesis and cell proliferation. Recent studies have shown potential for serum TK1 activity (sTKa) as a prognostic marker and indicator of early response to endocrine therapy in advanced breast cancer. The aim of this study is to assess the correlation between sTKa and patient outcome. Patients and methods: The Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) was a double-blind, double-dummy, randomised trial of fulvestrant versus exemestane after progression on non-steroidal aromatase inhibitor therapy, in postmenopausal women with advanced breast cancer. Retrospective analyses of serum archived from EFECT were conducted. sTKa was assessed using the DiviTum (R) assay on samples collected at baseline, after three and six months of endocrine therapy, and at disease progression. Results: The median time to progression (mTTP) for patients with low baseline sTKa levels was 5.03 months (95% confidence interval [CI]: 3.91-5.89) versus 2.57 months (95% CI: 2.04-3.52) in patients with high sTKa baseline levels (P < 0.0001). On treatment, patients whose sTKa increased from baseline had a significantly shorter mTTP (3.39 months, 95% CI: 2.14-4.11) than those without an sTKa increase (5.39 months, 95% CI: 4.01-6.68) (P = 0.0045). Similar results were observed in the separate EFECT treatment arms. After adjusting for major prognostic factors, sTKa remained an independent marker. Conclusion: sTKa is a potential circulating prognostic marker in patients with advanced breast cancer treated with endocrine therapy. It may also represent a tool for upfront identification of endocrine therapy resistance and early positive response to therapy. Independent validation of these results is warranted. (C) 2019 Elsevier Ltd. All rights reserved.

引用

页码：55 / 66

页数：12

共 25 条

[1]

Al-Madhoun AS, 2004, MINI-REV MED CHEM, V4, P341

[2]

Alegre MM, 2012, J ONCOL, V2012, P1

[3] Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib [J].

Bagegni, Nusayba ;

Thomas, Shana ;

Liu, Ning ;

Luo, Jingqin ;

Hoog, Jeremy ;

Northfelt, Donald W. ;

Goetz, Matthew P. ;

Forero, Andres ;

Bergqvist, Mattias ;

Karen, Jakob ;

Neumueller, Magnus ;

Suh, Edward M. ;

Guo, Zhanfang ;

Vij, Kiran ;

Sanati, Souzan ;

Ellis, Matthew ;

Ma, Cynthia X. .

BREAST CANCER RESEARCH, 2017, 19

[4] Intratumor Heterogeneity in Breast Cancer [J].

Beca, Francisco ;

Polyak, Kornelia .

NOVEL BIOMARKERS IN THE CONTINUUM OF BREAST CANCER, 2016, 882 :169-189

[5] Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial [J].

Bjohle, J. ;

Bergqvist, J. ;

Gronowitz, J. S. ;

Johansson, H. ;

Carlsson, L. ;

Einbeigi, Z. ;

Linderholm, B. ;

Loman, N. ;

Malmberg, M. ;

Soderberg, M. ;

Sundquist, M. ;

Walz, T. M. ;

Ferno, M. ;

Bergh, J. ;

Hatschek, T. .

BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) :751-758

[6] Serum Thymidine Kinase 1 Activity in Solid Tumor (Breast and Colorectal Cancer) Patients Treated With Adjuvant Chemotherapy [J].

Bolayirli, M. ;

Papila, C. ;

Korkmaz, G. G. ;

Papila, B. ;

Aydogan, F. ;

Karatas, A. ;

Uzun, H. .

JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2013, 27 (03) :220-226

[7]

Bonechi Martina, 2018, Oncotarget, V9, P16389, DOI 10.18632/oncotarget.24700

[8] Thymidine kinase as a proliferative marker:: Clinical relevance in 1,692 primary breast cancer patients [J].

Broët, P ;

Romain, S ;

Daver, A ;

Ricolleau, G ;

Quillien, V ;

Rallet, A ;

Asselain, B ;

Martin, PM ;

Spyratos, F .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2778-2787

[9] Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT [J].

Chia, Stephen ;

Gradishar, William ;

Mauriac, Louis ;

Bines, Jose ;

Amant, Frederic ;

Federico, Miriam ;

Fein, Luis ;

Romieu, Gilles ;

Buzdar, Aman ;

Robertson, John F. R. ;

Brufsky, Adam ;

Possinger, Kurt ;

Rennie, Pamela ;

Sapunar, Francisco ;

Lowe, Elizabeth ;

Piccart, Martine .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1664-1670

[10]

Foekens JA, 2001, CANCER RES, V61, P1421

← 1 2 3 →